Clinical Commissioning Policy Statement: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Document first published:
Page updated:
Topic:
Publication type:

Abatacept is recommended as a treatment option through routine commissioning for patients (adults and children 2 years and over) with severe, treatment resistant morphoea within the criteria set out in this document.

Document

Clinical commissioning policy - July 2021: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Clinical commissioning policy - July 2021: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 354 KB
  • 10 pages

Document

Clinical panel report - June 2020: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Clinical panel report - June 2020: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 98 KB
  • 4 pages

Document

Clinical priorities advisory group: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Clinical priorities advisory group: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 191 KB
  • 10 pages

Document

Evidence review: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Evidence review: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 445 KB
  • 43 pages

Document

Engagement review: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Engagement review: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 73 KB
  • 5 pages

Document

Equality and Health Inequalities Impact Assessment: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Equality and Health Inequalities Impact Assessment: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 101 KB
  • 9 pages

Document

Public health report: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

Public health report: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)

  • PDF
  • 81 KB
  • 5 pages